Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study.

Schmidt WE, Christiansen JS, Hammer M, Zychma MJ, Buse JB

Diabetic medicine : a journal of the British Diabetic Association1 Jun 2011Cited by 25 (Europe PMC)

PMID21388442PMCIDPMC3123703DOI10.1111/j.1464-5491.2011.03276.xPepBankPUB-21388442

Summary

AimsThe Liraglutide Effect and Action in Diabetes 6 trial was an open-label trial comparing liraglutide with exenatide as an 'add-on' to metformin and/or sulphonylurea.MethodsPatients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks. This was followed by a 14-week extension phase, in which all patients received liraglutide 1.8 mg once daily.ResultsPatient-reported outcomes were measured in 379 patients using Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and DTSQ change (DTSQc). The change in overall treatment satisfaction (DTSQs score) from baseline at week 26 with liraglutide was 4.71 and with exentaide was 1.66 [difference between groups 3.04 (95% CI 1.73-4.35), P<0.0001]. Five of the six items on the DTSQs improved significantly more with liraglutide than with exenatide (differences: current treatment 0.37, P=0.0093; convenience 0.68, P<0.0001; flexibility 0.57, P=0.0002; recommend 0.49, P=0.0003; continue 0.66, P=0.0001). Patients perceived a greater reduction in hypoglycaemia at week 26 with liraglutide than with exenatide [difference in DTSQc score 0.48 (0.08-0.89), P=0.0193] and a greater reduction in perceived hyperglycaemia [difference 0.74 (0.31-1.17), P=0.0007]. During the extension phase, when all patients received liraglutide, DTSQs scores remained stable in patients who continued on liraglutide and increased significantly (P=0.0026) in those switching from exenatide.ConclusionsThese results demonstrate significant improvements in patients' treatment satisfaction with liraglutide compared with exenatide.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study18

18 results from studies that gave the peptide. 18 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, overall treatment satisfaction rose more with liraglutide than with exenatide at week 26 (4.71 versus 1.66; difference 3.04, 95% CI 1.73-4.35; P<0.0001).
In plain wordsIn people with type 2 diabetes, liraglutide improved treatment satisfaction more than exenatide over 26 weeks.
Peptide
Liraglutide
Outcome
IncreaseChange in overall treatment satisfaction (DTSQs score) at week 26
Study
n = 379
Comparator
Exenatide 10 μg twice daily
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
The change in overall treatment satisfaction (DTSQs score) from baseline at week 26 with liraglutide was 4.71 and with exentaide was 1.66 [difference between groups 3.04 (95% CI 1.73-4.35), P<0.0001].
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844201
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, satisfaction with current treatment improved significantly more with liraglutide than with exenatide (difference 0.37, P=0.0093).
In plain wordsIn people with type 2 diabetes, satisfaction with current treatment improved more with liraglutide than with exenatide.
Peptide
Liraglutide
Outcome
IncreaseDTSQs item: current treatment
Study
n = 379
Comparator
Exenatide 10 μg twice daily
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Five of the six items on the DTSQs improved significantly more with liraglutide than with exenatide (differences: current treatment 0.37, P=0.0093; convenience 0.68, P<0.0001; flexibility 0.57, P=0.0002; recommend 0.49, P=0.0003; continue 0.66, P=0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844202
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, perceived convenience improved significantly more with liraglutide than with exenatide (difference 0.68, P<0.0001).
In plain wordsIn people with type 2 diabetes, liraglutide was rated more convenient than exenatide.
Peptide
Liraglutide
Outcome
IncreaseDTSQs item: convenience
Study
n = 379
Comparator
Exenatide 10 μg twice daily
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Five of the six items on the DTSQs improved significantly more with liraglutide than with exenatide (differences: current treatment 0.37, P=0.0093; convenience 0.68, P<0.0001; flexibility 0.57, P=0.0002; recommend 0.49, P=0.0003; continue 0.66, P=0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844203
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, perceived flexibility improved significantly more with liraglutide than with exenatide (difference 0.57, P=0.0002).
In plain wordsIn people with type 2 diabetes, liraglutide was rated more flexible than exenatide.
Peptide
Liraglutide
Outcome
IncreaseDTSQs item: flexibility
Study
n = 379
Comparator
Exenatide 10 μg twice daily
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Five of the six items on the DTSQs improved significantly more with liraglutide than with exenatide (differences: current treatment 0.37, P=0.0093; convenience 0.68, P<0.0001; flexibility 0.57, P=0.0002; recommend 0.49, P=0.0003; continue 0.66, P=0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844204
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, willingness to recommend the treatment improved significantly more with liraglutide than with exenatide (difference 0.49, P=0.0003).
In plain wordsIn people with type 2 diabetes, patients were more willing to recommend liraglutide than exenatide.
Peptide
Liraglutide
Outcome
IncreaseDTSQs item: recommend
Study
n = 379
Comparator
Exenatide 10 μg twice daily
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Five of the six items on the DTSQs improved significantly more with liraglutide than with exenatide (differences: current treatment 0.37, P=0.0093; convenience 0.68, P<0.0001; flexibility 0.57, P=0.0002; recommend 0.49, P=0.0003; continue 0.66, P=0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844205
06HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, willingness to continue the treatment improved significantly more with liraglutide than with exenatide (difference 0.66, P=0.0001).
In plain wordsIn people with type 2 diabetes, patients were more willing to continue liraglutide than exenatide.
Peptide
Liraglutide
Outcome
IncreaseDTSQs item: continue
Study
n = 379
Comparator
Exenatide 10 μg twice daily
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Five of the six items on the DTSQs improved significantly more with liraglutide than with exenatide (differences: current treatment 0.37, P=0.0093; convenience 0.68, P<0.0001; flexibility 0.57, P=0.0002; recommend 0.49, P=0.0003; continue 0.66, P=0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844206
07HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, patients perceived a greater reduction in hypoglycaemia with liraglutide than with exenatide at week 26 (difference in DTSQc score 0.48, 95% CI 0.08-0.89; P=0.0193).
In plain wordsIn people with type 2 diabetes, patients felt they had fewer low blood sugar episodes with liraglutide than with exenatide.
Peptide
Liraglutide
Outcome
DecreasePerceived hypoglycaemia (DTSQc score) at week 26
Study
n = 379
Comparator
Exenatide 10 μg twice daily
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Patients perceived a greater reduction in hypoglycaemia at week 26 with liraglutide than with exenatide [difference in DTSQc score 0.48 (0.08-0.89), P=0.0193] and a greater reduction in perceived hyperglycaemia [difference 0.74 (0.31-1.17), P=0.0007].
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844207
08HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, patients perceived a greater reduction in hyperglycaemia with liraglutide than with exenatide at week 26 (difference 0.74, 95% CI 0.31-1.17; P=0.0007).
In plain wordsIn people with type 2 diabetes, patients felt they had fewer high blood sugar episodes with liraglutide than with exenatide.
Peptide
Liraglutide
Outcome
DecreasePerceived hyperglycaemia (DTSQc score) at week 26
Study
n = 379
Comparator
Exenatide 10 μg twice daily
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Patients perceived a greater reduction in hypoglycaemia at week 26 with liraglutide than with exenatide [difference in DTSQc score 0.48 (0.08-0.89), P=0.0193] and a greater reduction in perceived hyperglycaemia [difference 0.74 (0.31-1.17), P=0.0007].
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844208
09HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, overall treatment satisfaction improved less with exenatide than liraglutide.
In plain wordsIn type 2 diabetes, treatment satisfaction improved less with exenatide than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseOverall treatment satisfaction change
Study
n = 379
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Patient-reported outcomes · Whole body
Studied dose
10 μg twice daily · 26 weeksAs given in this study (human).
Measurements
Change in overall treatment satisfaction (DTSQs)
1.66 score
exenatide, from baseline at week 26
Change in overall treatment satisfaction (DTSQs)
4.71 score
liraglutide, from baseline at week 26
Difference in DTSQs change
3.04 score
difference between groups (liraglutide versus exenatide)
95% CI of difference
1.73 to 4.35 score
difference between groups (liraglutide versus exenatide)
Source sentences
Summary
The change in overall treatment satisfaction (DTSQs score) from baseline at week 26 with liraglutide was 4.71 and with exentaide was 1.66 [difference between groups 3.04 (95% CI 1.73-4.35), P<0.0001].
3 context sentences(design, population, supporting numbers)
Summary · context
Patient-reported outcomes were measured in 379 patients using Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and DTSQ change (DTSQc).
Summary · context
The Liraglutide Effect and Action in Diabetes 6 trial was an open-label trial comparing liraglutide with exenatide as an 'add-on' to metformin and/or sulphonylurea.
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844211
10HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, satisfaction with current treatment improved less with exenatide than liraglutide.
In plain wordsIn type 2 diabetes, satisfaction with current treatment improved less with exenatide than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseCurrent treatment satisfaction
Study
n = 379
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Patient-reported outcomes · Whole body
Studied dose
10 μg twice daily · 26 weeksAs given in this study (human).
Measurements
DTSQs item difference: current treatment
0.37 score
difference between groups (liraglutide versus exenatide)
Source sentences
Summary
Five of the six items on the DTSQs improved significantly more with liraglutide than with exenatide (differences: current treatment 0.37, P=0.0093; convenience 0.68, P<0.0001; flexibility 0.57, P=0.0002; recommend 0.49, P=0.0003; continue 0.66, P=0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The Liraglutide Effect and Action in Diabetes 6 trial was an open-label trial comparing liraglutide with exenatide as an 'add-on' to metformin and/or sulphonylurea.
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844212
11HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, perceived treatment convenience improved less with exenatide than liraglutide.
In plain wordsIn type 2 diabetes, treatment convenience improved less with exenatide than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTreatment convenience
Study
n = 379
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Patient-reported outcomes · Whole body
Studied dose
10 μg twice daily · 26 weeksAs given in this study (human).
Measurements
DTSQs item difference: convenience
0.68 score
difference between groups (liraglutide versus exenatide)
Source sentences
Summary
Five of the six items on the DTSQs improved significantly more with liraglutide than with exenatide (differences: current treatment 0.37, P=0.0093; convenience 0.68, P<0.0001; flexibility 0.57, P=0.0002; recommend 0.49, P=0.0003; continue 0.66, P=0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The Liraglutide Effect and Action in Diabetes 6 trial was an open-label trial comparing liraglutide with exenatide as an 'add-on' to metformin and/or sulphonylurea.
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844213
12HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, perceived treatment flexibility improved less with exenatide than liraglutide.
In plain wordsIn type 2 diabetes, treatment flexibility improved less with exenatide than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTreatment flexibility
Study
n = 379
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Patient-reported outcomes · Whole body
Studied dose
10 μg twice daily · 26 weeksAs given in this study (human).
Measurements
DTSQs item difference: flexibility
0.57 score
difference between groups (liraglutide versus exenatide)
Source sentences
Summary
Five of the six items on the DTSQs improved significantly more with liraglutide than with exenatide (differences: current treatment 0.37, P=0.0093; convenience 0.68, P<0.0001; flexibility 0.57, P=0.0002; recommend 0.49, P=0.0003; continue 0.66, P=0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The Liraglutide Effect and Action in Diabetes 6 trial was an open-label trial comparing liraglutide with exenatide as an 'add-on' to metformin and/or sulphonylurea.
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844214
13HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, willingness to recommend treatment improved less with exenatide than liraglutide.
In plain wordsIn type 2 diabetes, willingness to recommend treatment improved less with exenatide than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWillingness to recommend treatment
Study
n = 379
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Patient-reported outcomes · Whole body
Studied dose
10 μg twice daily · 26 weeksAs given in this study (human).
Measurements
DTSQs item difference: recommend
0.49 score
difference between groups (liraglutide versus exenatide)
Source sentences
Summary
Five of the six items on the DTSQs improved significantly more with liraglutide than with exenatide (differences: current treatment 0.37, P=0.0093; convenience 0.68, P<0.0001; flexibility 0.57, P=0.0002; recommend 0.49, P=0.0003; continue 0.66, P=0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The Liraglutide Effect and Action in Diabetes 6 trial was an open-label trial comparing liraglutide with exenatide as an 'add-on' to metformin and/or sulphonylurea.
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844215
14HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, willingness to continue treatment improved less with exenatide than liraglutide.
In plain wordsIn type 2 diabetes, willingness to continue treatment improved less with exenatide than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWillingness to continue treatment
Study
n = 379
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Patient-reported outcomes · Whole body
Studied dose
10 μg twice daily · 26 weeksAs given in this study (human).
Measurements
DTSQs item difference: continue
0.66 score
difference between groups (liraglutide versus exenatide)
Source sentences
Summary
Five of the six items on the DTSQs improved significantly more with liraglutide than with exenatide (differences: current treatment 0.37, P=0.0093; convenience 0.68, P<0.0001; flexibility 0.57, P=0.0002; recommend 0.49, P=0.0003; continue 0.66, P=0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The Liraglutide Effect and Action in Diabetes 6 trial was an open-label trial comparing liraglutide with exenatide as an 'add-on' to metformin and/or sulphonylurea.
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844216
15HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, perceived hypoglycaemia declined less with exenatide than liraglutide.
In plain wordsIn type 2 diabetes, perceived low blood sugar declined less with exenatide than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePerceived hypoglycaemia reduction
Study
n = 379
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg twice daily · 26 weeksAs given in this study (human).
Measurements
Difference in DTSQc score, perceived hypoglycaemia
0.48 score
difference between groups (liraglutide versus exenatide)
95% CI of difference
0.08 to 0.89 score
difference between groups (liraglutide versus exenatide)
Source sentences
Summary
Patients perceived a greater reduction in hypoglycaemia at week 26 with liraglutide than with exenatide [difference in DTSQc score 0.48 (0.08-0.89), P=0.0193] and a greater reduction in perceived hyperglycaemia [difference 0.74 (0.31-1.17), P=0.0007].
2 context sentences(design, population, supporting numbers)
Summary · context
The Liraglutide Effect and Action in Diabetes 6 trial was an open-label trial comparing liraglutide with exenatide as an 'add-on' to metformin and/or sulphonylurea.
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844217
16HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, perceived hyperglycaemia declined less with exenatide than liraglutide.
In plain wordsIn type 2 diabetes, perceived high blood sugar declined less with exenatide than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePerceived hyperglycaemia reduction
Study
n = 379
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg twice daily · 26 weeksAs given in this study (human).
Measurements
Difference in DTSQc score, perceived hyperglycaemia
0.74 score
difference between groups (liraglutide versus exenatide)
95% CI of difference
0.31 to 1.17 score
difference between groups (liraglutide versus exenatide)
Source sentences
Summary
Patients perceived a greater reduction in hypoglycaemia at week 26 with liraglutide than with exenatide [difference in DTSQc score 0.48 (0.08-0.89), P=0.0193] and a greater reduction in perceived hyperglycaemia [difference 0.74 (0.31-1.17), P=0.0007].
2 context sentences(design, population, supporting numbers)
Summary · context
The Liraglutide Effect and Action in Diabetes 6 trial was an open-label trial comparing liraglutide with exenatide as an 'add-on' to metformin and/or sulphonylurea.
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844218
17HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes who continued liraglutide in the 14-week extension, treatment satisfaction scores remained stable.
In plain wordsIn people with type 2 diabetes who stayed on liraglutide, treatment satisfaction scores stayed stable during the extension.
Peptide
Liraglutide
Outcome
No significant changeDTSQs score in extension phase, continuing liraglutide
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
1.8 mg once daily · 14 weeksAs given in this study (human).
Source sentences
Summary
During the extension phase, when all patients received liraglutide, DTSQs scores remained stable in patients who continued on liraglutide and increased significantly (P=0.0026) in those switching from exenatide.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844209
18HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes who switched from exenatide to liraglutide in the 14-week extension, treatment satisfaction scores increased significantly (P=0.0026).
In plain wordsIn people with type 2 diabetes who switched from exenatide to liraglutide, treatment satisfaction scores rose.
Peptide
Liraglutide
Outcome
IncreaseDTSQs score in extension phase, switching from exenatide to liraglutide
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
1.8 mg once daily · 14 weeksAs given in this study (human).
Source sentences
Summary
During the extension phase, when all patients received liraglutide, DTSQs scores remained stable in patients who continued on liraglutide and increased significantly (P=0.0026) in those switching from exenatide.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks.
Show in the study text Report a problemFND-2138844210

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00518882

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 467Aug 2007 to Apr 2009

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 8 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.